Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases
Deep Apple Therapeutics, Inc. announced a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
• Under the terms of the agreement, Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.
• Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.
• Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately prior to the start of IND-enabling studies.
• Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk.
• In total, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from the collaboration.
• Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.
• Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.
• Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately prior to the start of IND-enabling studies.
• Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from the collaboration.
Deep Apple Therapeutics, Inc. announced a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
• “Novo Nordisk is a long-established global leader in delivering transformative treatments for cardiometabolic diseases, and the Deep Apple team is energized by the opportunity to collaborate with them,” said Spiros Liras, Ph.D., CEO of Deep Apple and a venture partner at Apple Tree Partners (ATP).
• “This programme highlights our platform capabilities in identifying potent, novel leads within months, and the partnership with Novo Nordisk will enable us to advance a first-in-class non-incretin program for cardiometabolic diseases.”
• “Novo Nordisk is developing a range of potential oral medicines for cardiometabolic diseases across modalities and targets, as we know that people living with these diseases have different needs and preferences,” said Jacob Sten Petersen, senior vice president, diabetes, obesity and MASH therapeutic area at Novo Nordisk.
• “We look forward to exploring this novel target further based on Deep Apple’s AI-powered platform and expertise in small molecule drug discovery.”
The target is a non-incretin G-protein coupled receptor (GPCR) that is well-suited for Deep Apple’s platform, which captures the dynamics and motion of GPCRs and other proteins in different conformations to reveal novel pockets that can be docked with Deep Apple’s proprietary virtual libraries.
• Founded by Apple Tree Partners (ATP), Deep Apple is pioneering a new approach to drug discovery.
• Utilizes ensemble cryo-EM to explore receptor conformations for advanced molecular targeting.
• Integrates deep learning to enhance predictive modeling and drug design accuracy.
• Leverages Orchard.ai, a proprietary algorithm, to dock multi-billion virtual compound libraries for therapeutic breakthroughs.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
Words from the CEO: Deep Apple contin……
• “Novo Nordisk is a long-established global leader in delivering transformative treatments for cardiometabolic diseases, and the Deep Apple team is energized by the opportunity to collaborate with them,” said Spiros Liras, Ph.D., CEO of Deep Apple and a venture partner at Apple Tree Partners (ATP).
• “This programme highlights our platform capabilities in identifying potent, novel leads within months, and the partnership with Novo Nordisk will enable us to advance a first-in-class non-incretin program for cardiometabolic diseases.”
• “Novo Nordisk is developing a range of potential oral medicines for cardiometabolic diseases across modalities and targets, as we know that people living with these diseases have different needs and preferences,” said Jacob Sten Petersen, senior vice president, diabetes, obesity and MASH therapeutic area at Novo Nordisk.
• “We look forward to exploring this novel target further based on Deep Apple’s AI-powered platform and expertise in small molecule drug discovery.”
The target is a non-incretin G-protein coupled receptor (GPCR) that is well-suited for Deep Apple’s platform, which captures the dynamics and motion of GPCRs and other proteins in different conformations to reveal novel pockets that can be docked with Deep Apple’s proprietary virtual libraries.
• Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
• Its purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!